The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.
Identifieur interne : 000679 ( PubMed/Corpus ); précédent : 000678; suivant : 000680The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.
Auteurs : M. Lagière ; S. Navailles ; L. Mignon ; A. Roumegous ; M-F Chesselet ; P. De DeurwaerdèreSource :
- Experimental brain research [ 1432-1106 ] ; 2013.
English descriptors
- KwdEn :
- Administration, Oral, Animals, Basal Ganglia (drug effects), Basal Ganglia (metabolism), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Electrophysiological Phenomena (physiology), Entopeduncular Nucleus (drug effects), Entopeduncular Nucleus (metabolism), Ethylamines (administration & dosage), Ethylamines (pharmacology), Globus Pallidus (drug effects), Globus Pallidus (metabolism), Indoles (administration & dosage), Indoles (pharmacology), Male, Neurons (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Rats, Rats, Sprague-Dawley, Serotonin (metabolism), Serotonin 5-HT2 Receptor Agonists (administration & dosage), Serotonin 5-HT2 Receptor Agonists (pharmacology), Substantia Nigra (drug effects), Substantia Nigra (metabolism).
- MESH :
- chemical , administration & dosage : Ethylamines, Indoles, Serotonin 5-HT2 Receptor Agonists.
- drug effects : Basal Ganglia, Corpus Striatum, Entopeduncular Nucleus, Globus Pallidus, Neurons, Substantia Nigra.
- drug therapy : Parkinson Disease.
- metabolism : Basal Ganglia, Corpus Striatum, Entopeduncular Nucleus, Globus Pallidus, Parkinson Disease, Serotonin, Substantia Nigra.
- chemical , pharmacology : Ethylamines, Indoles, Serotonin 5-HT2 Receptor Agonists.
- physiology : Electrophysiological Phenomena.
- Administration, Oral, Animals, Disease Models, Animal, Male, Rats, Rats, Sprague-Dawley.
Abstract
Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.
DOI: 10.1007/s00221-013-3478-4
PubMed: 23535834
Links to Exploration step
pubmed:23535834Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.</title><author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M" last="Lagière">M. Lagière</name><affiliation><nlm:affiliation>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name></author><author><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L" last="Mignon">L. Mignon</name></author><author><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A" last="Roumegous">A. Roumegous</name></author><author><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M-F" last="Chesselet">M-F Chesselet</name></author><author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23535834</idno><idno type="pmid">23535834</idno><idno type="doi">10.1007/s00221-013-3478-4</idno><idno type="wicri:Area/PubMed/Corpus">000679</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000679</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.</title><author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M" last="Lagière">M. Lagière</name><affiliation><nlm:affiliation>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name></author><author><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L" last="Mignon">L. Mignon</name></author><author><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A" last="Roumegous">A. Roumegous</name></author><author><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M-F" last="Chesselet">M-F Chesselet</name></author><author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name></author></analytic><series><title level="j">Experimental brain research</title><idno type="eISSN">1432-1106</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia (metabolism)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Electrophysiological Phenomena (physiology)</term><term>Entopeduncular Nucleus (drug effects)</term><term>Entopeduncular Nucleus (metabolism)</term><term>Ethylamines (administration & dosage)</term><term>Ethylamines (pharmacology)</term><term>Globus Pallidus (drug effects)</term><term>Globus Pallidus (metabolism)</term><term>Indoles (administration & dosage)</term><term>Indoles (pharmacology)</term><term>Male</term><term>Neurons (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Serotonin (metabolism)</term><term>Serotonin 5-HT2 Receptor Agonists (administration & dosage)</term><term>Serotonin 5-HT2 Receptor Agonists (pharmacology)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ethylamines</term><term>Indoles</term><term>Serotonin 5-HT2 Receptor Agonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Corpus Striatum</term><term>Entopeduncular Nucleus</term><term>Globus Pallidus</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term><term>Corpus Striatum</term><term>Entopeduncular Nucleus</term><term>Globus Pallidus</term><term>Parkinson Disease</term><term>Serotonin</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ethylamines</term><term>Indoles</term><term>Serotonin 5-HT2 Receptor Agonists</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Electrophysiological Phenomena</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Disease Models, Animal</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23535834</PMID><DateCreated><Year>2013</Year><Month>10</Month><Day>01</Day></DateCreated><DateCompleted><Year>2014</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1106</ISSN><JournalIssue CitedMedium="Internet"><Volume>230</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Experimental brain research</Title><ISOAbbreviation>Exp Brain Res</ISOAbbreviation></Journal><ArticleTitle>The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.</ArticleTitle><Pagination><MedlinePgn>513-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00221-013-3478-4</ELocationID><Abstract><AbstractText>Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagière</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navailles</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mignon</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Roumegous</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chesselet</LastName><ForeName>M-F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>De Deurwaerdère</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50-NS 38367</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37-MH44894</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Exp Brain Res</MedlineTA><NlmUniqueID>0043312</NlmUniqueID><ISSNLinking>0014-4819</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005021">Ethylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C103848">Ro 60-0175</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058826">Serotonin 5-HT2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055724" MajorTopicYN="N">Electrophysiological Phenomena</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020392" MajorTopicYN="N">Entopeduncular Nucleus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005021" MajorTopicYN="N">Ethylamines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005917" MajorTopicYN="N">Globus Pallidus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058826" MajorTopicYN="N">Serotonin 5-HT2 Receptor Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23535834</ArticleId><ArticleId IdType="doi">10.1007/s00221-013-3478-4</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000679 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000679 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23535834
|texte= The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23535834" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |